LOGOLOGOLOGOLOGO
    • About us
      • What we do
      • Who we are
        • Governance
        • Staff
        • Vacancies
    • Members
      • EuropaBio Members
      • About Membership
    • How we work
      • Healthcare Biotechnology Council
        • Patient BioForum
        • Study – Impact of the EU’s General Pharmaceutical Legislation
      • Industrial Biotechnology Council
        • EFIB
        • Microorganisms
      • National Associations Council
      • SME Platform
      • Biomanufacturing Platform
        • Biotechnology in our Lives
    • Activities
      • 25 Years of Innovation
      • The EU Biotech Act
      • European Biotech Week
      • EU Projects
        • PRIMED Project
        • APROVALS Project
    • News & Events
      • News
      • Events
    • Library
    Become a member
    ✕

    OM Pharma joins EuropaBio: Transforming Immune Health

    18/11/2024

    PRESS RELEASE

    Brussels, 18 November 2024 - EuropaBio is delighted to announce that OM Pharma, a Swiss multinational biotech company has joined its membership.

    With nearly a 100-year history, OM Pharma is focussed on transforming immune health using bacterial lysates - medicines which help prime the immune system to prevent infections.

    Manufactured from end-to-end on their biotech campus and headquarters in Geneva, lysates have the potential to help address some of today’s most pressing global health challenges including Antimicrobial Resistance (AMR).

    Beyond a focus on bacteria-based products, OM Pharma also globally markets small molecules for the treatment of vascular diseases and has a large portfolio of trusted brands in Switzerland and Latin America. OM Pharma products are available in more than 100 countries through a network of trusted partners.

    In joining EuropaBio, OM Pharma will bring its expertise as a fully integrated biotech company, covering all areas from API production to commercialisation of finished products in Europe. It seeks to raise the awareness of biotechnology derived therapeutics that protect against and mitigate infectious diseases and reduce the use of antibiotics, while helping to boost the biotechnology & biomanufacturing sector within Europe and beyond.

    Dr. Claire Skentelbery, Director General of EuropaBio commented, “OM Pharma is an excellent example of Europe’s capacity within healthcare biotechnology, combining innovation and manufacturing. We are delighted to welcome Christian and the team into EuropaBio at this vital phase of ambition for biotech within policy, and will bring their voices to help turn ambition into the legislation.”

    Christian Terreaux, Director Public Affairs for OM Pharma added "With a series of global health challenges looming large, joining forces with EuropaBio helps us become part of a respected community driving for progress in the biotech sector and contributing to policy change for a healthier Europe.”

    For more information on OM Pharma, please visit www.ompharma.com

    OM Pharma joins EuropaBio: Transforming Immune Health


    Download
    Share
    Adrian Lincoln
    Adrian Lincoln

    Related posts

    18/05/2026

    Biodefence & Biosecurity in focus for EuropaBio with dedicated Task Force


    Read more
    12/05/2026

    ‘Consistency, cooperation and practicality are the watch words’. EuropaBio reacts to provisional agreement on the Critical Medicines Act


    Read more
    08/05/2026

    Technovative Solutions Ltd. joins EuropaBio: Advancing AI‑Driven and Sustainable Innovation in Biotechnology


    Read more

    Important links

    • Biodefence & Biosecurity in focus for EuropaBio with dedicated Task Force
    • ‘Consistency, cooperation and practicality are the watch words’. EuropaBio reacts to provisional agreement on the Critical Medicines Act

    Categories in our Newsroom

    EBIO-white

    EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

    Contact us

    Extra links

    Members
    Staff
    Privacy policy
    Legal & cookies
    Events
    Newsroom

    Become a member

    Media pack

    © 2026 Europabio. All Rights Reserved. Designed by EYAS
    Become a member

    Vitamin B2

    The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

    Insulin

    Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.

    Detergents

    Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

    Clothes

    Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

    Algal Omega 3

    Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

    Cheese

    Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.